Skip to main
LH
LH logo

LH Stock Forecast & Price Target

LH Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Labcorp Holdings has demonstrated robust revenue growth, with Central Lab revenue increasing by 7.5% to reach $554.7 million, bolstered by notable trial wins and advancements in digital pathology capabilities. The company maintains a strong backlog of $8.71 billion, reflecting a year-over-year growth of approximately 10%, along with a trailing twelve-month net book-to-bill ratio of 1.11, indicating effective management of new business and client retention. Additionally, the Diagnostic segment reported revenue of $2.75 billion, marking an 8.9% year-over-year gain driven equally by organic growth and acquisitions, demonstrating Labcorp's resilience and strategic positioning in the competitive independent lab market.

Bears say

Labcorp Holdings faces several fundamental risks that contribute to a negative outlook on its stock, including adverse reimbursement changes under the Protecting Access to Medicare Act (PAMA) and challenges related to poor acquisition integration. The company is also under pressure from increasing competition within the clinical laboratory sector, which could hinder its market position, and economic uncertainty that may affect demand for its services. Additionally, potential regulatory challenges concerning laboratory-developed tests (LDTs) add further risk to its operational stability and financial performance.

LH has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Labcorp Holdings Inc (LH) Forecast

Analysts have given LH a Buy based on their latest research and market trends.

According to 13 analysts, LH has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $299, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $299, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Labcorp Holdings Inc (LH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.